ECS Launches UK Branded Portfolio with Curaleaf

Summary by 6ix AI

The agreement includes the distribution and manufacturing of six Australian-grown medicinal cannabis flower products, with initial supply targeted for a future date. ECS will retain ownership of the products until sold, allowing for direct exposure to market sales. This move is part of ECS's strategy to expand its international branded product offerings and leverage existing infrastructure in the UK.

Written by 6ix AI from the company’s filing. How 6ix writes summaries